Literature DB >> 9657535

Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome--a study in borderline hypertension.

C Lemne1, K Brismar.   

Abstract

AIM: To evaluate insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein-1 (IGFBP-1) in borderline hypertension (BHT) in relation to plasma lipoprotein and insulin levels, anthropometric variables and 24-h ambulatory blood pressure (BP). Seventy-five BHT men diastolic BP (DBP) 85-94 mmHg) and 75 age-matched normotensive controls (NT, DBP < or = 80 mmHg) were recruited from a population-based screening program.
RESULTS: There was no difference in IGF-I or IGFBP-1 between BHT and NT men. However, subjects with insulin resistance (IR) had decreased levels of IGF-1 (145 +/- 36 vs 153 +/- 28 microg/L, p < 0.05) and IGFBP-1 (41 +/- 15 vs 52 +/- 20 microg/L, p < 0.01) compared to those without IR. IGF-I correlated inversely to BP levels in the BHT group (r = -0.24 to -0.28, p < 0.05). IGFBP-1 correlated inversely with BMI, lipoprotein and insulin levels (r = -0.29 to -0.48, p < 0.01), independent of IR.
CONCLUSION: While there are no differences between BHT and NT men in IGF-I and IGFBP-1, both are significantly decreased in IR subjects. IGFBP-1 exhibits a close correlation to metabolic factors. Decreased IGFBP-1 could thus be suggested as a variable marking the "metabolic syndrome" of hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657535

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  8 in total

Review 1.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

2.  Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women.

Authors:  Luxia Zhang; Gary C Curhan; John P Forman
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

3.  Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model.

Authors:  Ashley Gray; William J Aronson; R James Barnard; Hemal Mehta; Junxiang Wan; Jonathan Said; Pinchas Cohen; Colette Galet
Journal:  J Endocrinol       Date:  2011-09-08       Impact factor: 4.286

4.  Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study.

Authors:  Sophie Norenstedt; Ylva Pernow; Kerstin Brismar; Maria Sääf; Ayla Ekip; Fredrik Granath; Jan Zedenius; Inga-Lena Nilsson
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

5.  Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19.

Authors:  Parisa Feizollahi; Somaieh Matin; Seyed Askar Roghani; Shayan Mostafaei; Elham Safarzadeh; Mahdi Taghadosi
Journal:  Inflammopharmacology       Date:  2022-01-31       Impact factor: 5.093

6.  Association between polymorphism at IGF-1 rs35767 gene locus and long-term decline in renal function: a Japanese retrospective longitudinal cohort study.

Authors:  Kosuke Honda; Satoru Kuriyama; Kimiyoshi Ichida; Tomoko Nakano; Naoki Sugano; Takashi Yokoo
Journal:  BMC Nephrol       Date:  2021-06-02       Impact factor: 2.388

Review 7.  The insulin-like growth factor system and nutritional assessment.

Authors:  Callum Livingstone
Journal:  Scientifica (Cairo)       Date:  2012-07-08

8.  Predictors of normalized HbA1c after gastric bypass surgery in subjects with abnormal glucose levels, a 2-year follow-up study.

Authors:  Neda Rajamand Ekberg; Henrik Falhammar; Erik Näslund; Kerstin Brismar
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.